Skip to main
MRK

Merck (MRK) Stock Forecast & Price Target

Merck (MRK) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 22%
Buy 39%
Hold 39%
Sell 0%
Strong Sell 0%

Bulls say

Merck & Co is poised for strong growth through the next decade, with key products such as Keytruda, Gardasil, and a strong pipeline in the works. Particularly, the CADENCE presentation provided robust data that demonstrates the potential for Merck's Winrevair franchise to drive significant sales growth. Additionally, the company's focus on sustainability and their plan to reinvest in strategic growth areas are indicative of a company with a strong long-term outlook.

Bears say

Merck & Co is facing significant challenges in the highly competitive pharmaceutical industry, as it tries to gain market share for its blockbuster drugs Keytruda and Gardasil while facing potential risks in its clinical trials. They recently reported exceptional results for their TTCW endpoint, but it remains to be seen if these positive results can be sustained. Additionally, the company's integration of sustainability into its business operations is commendable, but it remains to be seen if it will have a meaningful impact on their financial performance.

Merck (MRK) has been analyzed by 18 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 39% recommend Buy, 39% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Merck and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Merck (MRK) Forecast

Analysts have given Merck (MRK) a Buy based on their latest research and market trends.

According to 18 analysts, Merck (MRK) has a Buy consensus rating as of Apr 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $125.28, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $125.28, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Merck (MRK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.